GlassScriptPhysician profile
Gregory S Ahearn
NPI 1598772931
$144,118.60
in general payments reported to CMS, 2019-2025
18 companies · $34.53 in 2025
The $34.53 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $20K · 2021: $28K · 2022: $26K · 2023: $30K · 2024: $512 · 2025: $34.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $1,935 · Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,660.00 |
| Travel and Lodging | $1,935.19 |
| Food and Beverage | $1,822.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $87,789.18 | 2019-2024 | Orenitram, Remodulin, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $54,834.62 | 2020-2023 | Uptravi, Opsumit |
| Inari Medical, INC. | $563.80 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $207.29 | 2022-2025 | Avycaz, Dalvance, Teflaro |
| Genzyme Corporation | $154.42 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $136.19 | 2022-2023 | Dificid, Pifeltro, Delstrigo |
| Bayer Healthcare Pharmaceuticals INC. | $113.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.62 | 2020-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $41.66 | 2023 | Fasenra, Tezspire |
| Amgen INC. | $39.69 | 2022-2023 | Tavneos |
| Regeneron Healthcare Solutions, INC. | $36.52 | 2022-2023 | Dupixent |
| Olympus America INC. | $20.12 | 2022 | |
| Philips North America LLC | $17.69 | 2023 | |
| Pfizer INC. | $17.04 | 2023 | |
| Vifor Pharma, INC. | $15.96 | 2024 | Zemaira |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $15.93 | 2022 | |
| Viiv Healthcare Company | $15.81 | 2024 | Rukobia |
| Gilead Sciences, INC. | $14.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ahearn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.